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Abstract
Background:  We sought to evaluate the hypothesis that the high incidence of cutaneous
melanoma in white persons in central Alabama is associated with a predominance of Irish and Scots
descent.
Methods: Frequencies of country of ancestry reports were tabulated. The reports were also
converted to scores that reflect proportional countries of ancestry in individuals. Using the scores,
we computed aggregate country of ancestry indices as estimates of group ancestry composition.
HLA-DRB1*04 allele frequencies and relationships to countries of ancestry were compared in
probands and controls. Results were compared to those of European populations with HLA-
DRB1*04 frequencies.
Results: Ninety evaluable adult white cutaneous melanoma probands and 324 adult white controls
reported countries of ancestry of their grandparents. The respective frequencies of Ireland, and
Scotland and "British Isles" reported countries of ancestry were significantly greater in probands
than in controls. The respective frequencies of Wales, France, Italy and Poland were significantly
greater in controls. 16.7% of melanoma probands and 23.8% of controls reported "Native
American" ancestry; the corresponding "Native American" country of ancestry index was not
significantly different in probands and controls. The frequency of HLA-DRB1*04 was significantly
greater in probands, but was not significantly associated with individual or aggregate countries of
ancestry. The frequency of DRB1*04 observed in Alabama was compared to DRB1*04 frequencies
reported from England, Wales, Ireland, Orkney Island, France, Germany, and Australia.
Conclusion: White adults with cutaneous melanoma in central Alabama have a predominance of
Irish, Scots, and "British Isles" ancestry and HLA-DRB1*04 that likely contributes to their high
incidence of cutaneous melanoma.
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Background
The incidence of cutaneous melanoma in Alabama is high
(16.9 and 8.6 per 100,000 men and women, respectively,
in 1998) [1]. The average annual incidence rate in Ala-
bama during 1996 was 15.5 per 100,000 for men and 8.8
per 100,000 for women, indicating that the incidence in
men is increasing. This is consistent with reports that cuta-
neous melanoma is one of few cancers the incidence and
mortality of which is increasing in white Americans [2].
Lifestyle, sun exposure, fair skin, light eye color, poor abil-
ity to tan, Northern European or Celtic ethnicity, family
history of melanoma, benign nevi, various major histo-
compatibility complex alleles, and mutations in the p16
gene have been reported as risk factors for cutaneous
melanoma [3-16]. HLA-DRB1*04 is significantly associ-
ated with cutaneous melanoma in white persons in Ala-
bama [9] and Australia [11,12]. In addition, HLA-
DRB1*04 was reported positively associated with cutane-
ous melanoma in white patients who had a high index of
Celtic ancestry [14].
It has been hypothesized that the high incidence of
melanoma in Alabama, a Sunbelt state with a mild cli-
mate, is due to the settlement of Alabama by a predomi-
nance of persons of Irish and Scots descent [8-10]. In the
present study, we sought to evaluate this hypothesis by
using questionnaires to obtain information about the
countries of ancestry of the grandparents of white adults
in central Alabama with cutaneous melanoma and of
white control subjects from the central Alabama general
population. Using data from the questionnaires, we eval-
uated the frequency of country of ancestry reports in cuta-
neous melanoma and control participants and computed
country of ancestry indices to permit quantification and
comparison of group ancestry data, as previously
described [17]. We also compared HLA-DRB1*04 fre-
quencies in participants with melanoma who reported
"Celtic" and "non-Celtic" ancestry. The rationale for using
country of ancestry information and HLA-DRB1*04 to
identify persons who have increased risk to develop cuta-
neous melanoma is discussed.
Methods
General criteria for selection of study subjects
The performance of this work was approved by the Insti-
tutional Review Boards of the University of Alabama at
Birmingham and Brookwood Medical Center. All subjects
were adults (≥ 18 years of age) who were central Alabama
residents; each identified himself/herself as white. Per-
sons with melanoma were diagnosed in routine medical
care in the interval 1981 – 2002, but were otherwise unse-
lected. We excluded persons of sub-Saharan African or
African American descent, because most of these persons
have non-European ancestry and their incidence of cuta-
neous melanoma is much lower than in white persons in
central Alabama [1,2].
Melanoma probands
Cutaneous melanoma was diagnosed as previously
described [9]. HLA-DRB1 typing was performed by either
the microdroplet lymphocytotoxicity test using B-lym-
phocytes isolated by the nylon wool column procedure,
or by low-resolution SSP using genomic DNA obtained
from peripheral blood buffy coat, as previously described
[9,18]. Further, we included only the first persons diag-
nosed to have cutaneous melanoma in respective families;
they were designated as probands.
Control subjects
Adult control subjects residing in central Alabama were
recruited in two groups. The first group consisted of 83
spouses of persons with cutaneous melanoma and ran-
domly recruited subjects. The second group consisted of
260 unselected volunteers who completed the present
questionnaire (described below); they were recruited
from hospital workers, employees of two universities,
spouses of patients who attended a hematology/medical
oncology outpatient clinic, and members of the general
public encountered in two retail shopping malls. In both
groups, we excluded persons who were known to be rela-
tives of other study participants. We did not evaluate med-
ical histories or perform physical examinations in control
subjects. These data were pooled to yield a group of 343
unrelated controls, of whom 24 were eliminated because
they did not know the country of ancestry of any of their
grandparents (as indicated below). This left a group of
319 control subjects whose data were deemed evaluable
for the present study. HLA typing was performed on some
control subjects as indicated below.
Questionnaire and interview design
A one-page questionnaire was designed to permit each
study participant to indicate the countries of ancestry of
his/her paternal and maternal grandparents. This method
is identical to that previously validated in a study of the
ancestry of hemochromatosis probands [17]; in part, this
method was modified from previously reported methods
by including only the country of birth of grandparents
[6,14,19].
We defined aggregate country categories as the composite
of reports from respective countries [17]. Reports based
solely on association of family names with specific coun-
tries were tabulated as "Don't Know." Reports from partic-
ipants for whom each of four grandparents were
categorized as "Don't Know" were defined as inevaluable
and were excluded from final analysis [17]. We did not
evaluate relationships of country of ancestry to gender ofBMC Cancer 2004, 4:47 http://www.biomedcentral.com/1471-2407/4/47
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the grandparents or to the paternal or maternal side of the
participant's family [17].
Frequencies of countries of ancestry reports
We tabulated the number of participants who reported
specific countries of ancestry or aggregate country catego-
ries (as defined above) for one or more grandparents. This
method is identical to that previously described [17]; in
part, this method was modified from previously reported
methods by including only the country of birth of grand-
parents [14,19].
Country of ancestry indices
The questionnaire and interview reports from each partic-
ipant were evaluated to yield individual country of ances-
try scores that reflect proportional national ancestry, as
previously described [17]. We also computed aggregate
country of ancestry indices for cutaneous melanoma
probands and control subjects as estimates of group
ancestry composition. These indices were expressed as the
quotient of total individual scores for respective countries
and the total number of cutaneous melanoma probands
or control subjects, as appropriate [17].
Index of "Celtic" ancestry
An index of Celtic ancestry was computed in a manner
similar to that used for country of ancestry indices. In the
present analysis, persons who reported one or more
grandparents whose country of origin was Ireland or Scot-
land were defined as "Celts." Other participants were
defined as "non-Celts." We did not use grandparental sur-
names or maiden names to quantify the degree of Celtic
ancestry as did previous investigators [14,19].
Review of HLA-DRB1*04 phenotype frequencies in europe 
and australia
A manual and computerized literature search was per-
formed to identify reports of HLA-DRB1*04 phenotype
frequencies in white persons with or without melanoma
in countries or areas of Europe and Australia that are
known to have had Celt settlements The HLA-DRB1*04
phenotype frequency among white control subjects in
central Alabama is approximately 0.2148, based on the
combined data from two previous reports [9,20]. Thus, we
tabulated only those reports from countries or regions in
which the HLA-DRB1*04 phenotype frequency was >
0.2148. We excluded studies which reported HLA-
DRB1*04 frequency estimates on control cohorts of fewer
than 100 subjects.
Statistical considerations
The dataset consisted of observations on 90 cutaneous
melanoma probands and two groups of controls (83
interview subjects and 261 questionnaire responders,
respectively). A computer spreadsheet (Excel 2000, Micro-
soft Corp., Redmond, WA) and a statistical program (GB-
Stat, v. 8.0 2000, Dynamic Microsystems, Inc., Silver
Spring, MD) were used to perform the present analyses. In
a preliminary evaluation, we determined that the propor-
tions of men and women, mean ages, country of ancestry
reports, and frequencies of country of ancestry reports
were not significantly different in the two control groups.
Therefore, we pooled data from the two groups for com-
parison with those of melanoma probands. Frequencies
of men and women, clinical abnormalities, and countries
of ancestry were counted. General descriptive data are pre-
sented as percentages or mean ± 1 S.D. Comparisons
between groups were tested for statistical differences using
chi-square analysis, Fisher exact test or two-tailed Student
t test, as appropriate. However, Student t-test can not be
used to compare country of ancestry data groups in which
all values are 0 (no variability). Accordingly, we arbitrarily
assigned a country of ancestry datum of 0.25 for one per-
son in each proband country group for which there were
no actual country of ancestry reports. Student t-test was
then performed using this modified data group; estimated
p values from these tests are displayed in parentheses. A p
value < 0.05 was defined as significant. Odds ratios (OR)
were calculated as described by Woolf [21].
Results
Characteristics of cutaneous melanoma probands
There were reports from 90 evaluable probands (46 men,
44 women). Their mean age at the time of participation in
the present study was 49 ± 16 years (range 19 – 80 years).
Characteristics of control subjects
There were reports from 319 evaluable control subjects
(128 men, 191 women). The percentages of men and
women in the control group were similar to those in the
cutaneous melanoma probands (p = 0.0621, chi square
analysis). Their mean age at the time of participation in
the present study was 43 ± 16 years (range 18 – 82 years).
The mean age of the cutaneous melanoma probands was
significantly greater than that of the control subjects (49 ±
16 years vs. 43 ± 16 years, respectively; p = 0.0016).
General analysis of questionnaire and interview reports
No person declined to participate in the study, and there
were no incomplete, equivocal, or unintelligible ques-
tionnaire or interview reports. Some participants reported
that they were unaware of their ancestry due to adoption,
family estrangement, or disinterest in genealogy. Ninety
of 110 cutaneous melanoma probands (81.8%) and 319
of 347 control subjects (91.3%) provided reports for at
least one of four grandparents; these differences were sig-
nificant (p = 0.0026). Data from these participants were
included for further analysis. Thus, there were reports
from 90 evaluable cutaneous melanoma probands and
319 evaluable control subjects. Among evaluableBMC Cancer 2004, 4:47 http://www.biomedcentral.com/1471-2407/4/47
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cutaneous melanoma probands, the mean number of
countries reported was 2.2 ± 1.1 (range 1 – 5 countries).
The mean number of countries reported by evaluable con-
trol subjects was similar (2.4 ± 1.1 countries (range 1 – 7
countries); p = 0.2246).
Frequencies of country of ancestry reports
These data are displayed in Table 1. Most participants
reported European countries of ancestry. Frequencies of
Ireland and Scotland country reports of ancestry obtained
from cutaneous melanoma probands were significantly
greater than those from control subjects (p = 0.0042, OR
= 2.0 and p = 0.0015, OR = 2.2, respectively). The "Celtic"
country reports of ancestry was also significantly higher in
melanoma probands than in control subjects (Table 1).
The frequency of "British Isles" and "Europe Not British
Isles" ancestry reports tabulated in cutaneous melanoma
probands were not significantly different than those in
controls subjects. The respective frequencies of Wales,
France, Italy, and Poland ancestry reported by cutaneous
melanoma probands were significantly lower than those
in control subjects (Table 1). 16.7% of country of ancestry
reports from cutaneous melanoma probands and 23.8%
in control subjects indicated "Native American" ancestry;
these percentages were not significantly different (Table
1). The percentage of cutaneous melanoma probands who
reported "Don't Know" for the countries of ancestry of
one, two, or three grandparents was similar to that in con-
trol subjects (30.0% vs. 30.1%, respectively) (Table 1).
Table 1: Frequencies of Country of Ancestry Reports in Adult Whites in Central Alabama. *
Country Melanoma Probands % (n) Control Subjects % (n) P Value†
England 46.7 (42) 43.9 (140) 0.6394
Ireland 62.2 (56) 45.1 (144) 0.0042
Scotland 44.4 (40) 27.0 (86) 0.0015
Ireland + Scotland ("Celts") 67.8 (61) 55.8 (178) 0.0417
Wales 0 (0) 4.7 (15) 0.0223
British Isles 73.3 (66) 75.6 (241) 0.6679
Native American 16.7 (15) 23.8 (76) 0.1493
Germany 24.4 (22) 33.5 (107) 0.1009
France 5.6 (5) 14.1 (45) 0.0287
Norway 1.1 (1) 1.6 (5) 0.6059
Netherlands 6.7 (6) 9.1 (29) 0.4678
Lithuania 0 (0) 0.3 (1) 0.7800
Czechoslovakia 1.1 (1) 0.9 (3) 0.6315
Spain 0 (0) 2.2 (7) 0.1730
Austria 1.1 (1) 2.2 (7) 0.4442
Belgium 1.1 (1) 0.3 (1) 0.3921
Denmark 1.1 (1) 1.6 (5) 0.6059
Finland 0 (0) 0.3 (1) 0.7800
Greece 2.2 (2) 1.3 (4) 0.3941
Hungary 1.1 (1) 0.6 (2) 0.5265
Italy 0 (0) 5.6 (18) 0.0102
Poland 0 (0) 5.0 (16) 0.0172
Romania 0 (0) 0.6 (2) 0.6079
Russia 0 (0) 2.5 (8) 0.1343
Sicily 0 (0) 1.6 (5) 0.2866
Sweden 1.1 (1) 4.4 (14) 0.1211
Switzerland 0 (0) 1.3 (4) 0.3685
Europe Not British Isles 63.3 (57) 62.7 (200) 0.9120
North, Central, and South 
American Countries
4.4 (4) 2.2 (7) 0.2057
Near and Middle East Countries 1.1 (1) 0.9 (3) 0.6315
African Countries 0 (0) 0.3 (1) 0.7800
Don't Know 30.0 (27) 30.1 (96) 0.9863
*These data include all reports by each evaluable study participant; there were 90 evaluable melanoma probands and 319 evaluable control subjects. 
The category "British Isles" was defined as the reports in England, Ireland, Scotland, and Wales categories. The category "Europe Not British Isles" 
is comprised of the composite data from the corresponding individual countries displayed in the present table. Participants who indicated specific 
"Native American" ancestry most frequently reported Cherokee and Creek descent. The "North, Central, and South America Countries" category 
(other than "Native Americans") included Canada, U.S., Virgin Islands, Colombia, and Brazil. The category "Near and Middle East Countries" 
included reports about grandparents from Iran, Lebanon, and Syria. The single observation in "African Countries" represents the Republic of South 
Africa. The "Don't Know" categories include data from participants who reported this category for one, two, or three grandparents. †Chi-square or 
Fisher exact tests were used, as appropriate; p values < 0.05 were defined as significant.BMC Cancer 2004, 4:47 http://www.biomedcentral.com/1471-2407/4/47
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Country of ancestry indices
These data are displayed in Table 2. The respective Ireland
and Scotland indices in cutaneous melanoma probands
were significantly greater than those in control subjects.
The "Celtic" ancestry index was significantly higher in
melanoma probands than in control subjects. The
aggregate "British Isles" index was also significantly
greater in melanoma probands (Table 2). The Wales,
France, Spain, Austria, Italy, Poland, Russia, Sweden and
"Europe Not British Isles" indices in probands were signif-
icantly lower than those in control subjects (Table 2).
There were no other significant differences.
Table 2: Country of Ancestry Indices in Adult Whites in Central Alabama. *
Country Melanoma Probands Control Subjects p Value†
England 0.6559 0.7755 0.2896
Ireland 0.9573 0.6603 0.0150
Scotland 0.5924 0.3038 0.0031
Ireland + Scotland ("Celts") 1.5500 0.9640 0.0002
Wales 0 0.0674 (0.0005)
British Isles 2.2057 1.8069 0.0032
Native American 0.3184 0.2998 0.8493
Germany 0.4370 0.4610 0.8081
France 0.0889 0.1888 0.0001
Norway 0.0222 0.0230 0.9770
Netherlands 0.0903 0.1089 0.6909
Lithuania 0 0.0031 (0.9323)
Czechoslovakia 0.0037 0.0125 0.2967
Spain 0 0.0219 (0.0442)
Austria 0.0028 0.0214 0.0486
Belgium 0.0111 0.0031 0.4951
Denmark 0.0073 0.0167 0.3996
Finland 0 0.0063 (0.6110)
Greece 0.0203 0.0408 0.4491
Hungary 0.0222 0.0094 0.5863
Italy 0 0.1129 (0.0002)
Poland 0 0.0512 (0.0006)
Romania 0 0.0157 (0.3308)
Russia 0 0.0439 (0.0111)
Sicily 0 0.0392 (0.0667)
Sweden 0.0111 0.0674 0.0186
Switzerland 0 0.0157 (0.1400)
Europe Not British Isles 0.7169 1.2628 0.0001
North, Central, and South 
American Countries
0.1000 0.0533 0.4378
Near and Middle East Countries 0.0444 0.0408 0.9407
African Countries 0 0.0063 (0.6110)
Don't Know 0.5778 0.5235 0.6126
* These data include all reports by each evaluable study participant. The questionnaire and interview reports from each participant were evaluated 
to yield individual country of ancestry scores which reflect proportional national ancestry. For this, each participant was assigned 4.00 points 
divided equally among each of his/her 4 grandparents. If a participant indicated 2 or more countries of ancestry for a grandparent, the 1.00 point for 
that grandparent was equally divided among the respective countries to formulate the scores of individual participants. We also computed 
aggregate country of ancestry indices for melanoma probands and control subjects as estimates of group ancestry composition. These indices were 
expressed as the quotient of total individual scores for respective countries and the total number of melanoma probands or control subjects, as 
appropriate. The category "British Isles" was defined as the reports in England, Ireland, Scotland, and Wales categories. The category "Europe not 
British Isles" is comprised of the composite data from the corresponding individual countries displayed in the present table. Participants who 
indicated specific "Native American" ancestry most frequently reported Cherokee and Creek descent. The "North, Central, and South America 
Countries" category (other than "Native Americans") included Canada, United States, Virgin Islands, Colombia, and Brazil. The category "Near and 
Middle East Countries" included reports about grandparents from Iran, Lebanon, and Syria. The single observation in "African Countries" 
represents the Republic of South Africa. The "Don't Know" categories include data from participants who reported this category for one, two, or 
three grandparents. † Student t test cannot be used to compare country of ancestry data groups in which all values were 0 (no variability). 
Accordingly, we arbitrarily assigned a country of ancestry datum of 0.25 for one person in each proband country group for which there were no 
actual country of ancestry reports. Student t test was then performed using this modified data group; estimated values of p from these tests are 
displayed in parentheses.BMC Cancer 2004, 4:47 http://www.biomedcentral.com/1471-2407/4/47
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HLA-DRB1*04 frequencies
HLA-DRB1 phenotypes were available for 63 of the 90
present cutaneous melanoma probands. We divided the
probands for which we had both country of ancestry data
and HLA-DRB1 phenotypes into "Celts" (n = 19) and
"non-Celts" (n = 44), as defined above. There was no sig-
nificant difference in the frequency of HLA-DRB1*04 in
the two groups (0.5263 vs. 0.3636, respectively; p =
0.3551, OR = 1.9). Because this finding was unexpected
and differed from that of previous reports [14] we then
computed the frequencies of HLA-DRB1*04 in Alabama
white cutaneous melanoma probands and in control sub-
jects from two previous Alabama reports [9,20]. Thus, the
frequency of HLA-DRB1*04 in 123 probands (38.2%)
was significantly different from that in 340 controls
(21.5%) (p = 0.0005, OR = 2.3).
DRB1*04 phenotype frequencies > 0.2148 in Europe and 
Australia
We identified HLA-DRB1*04 phenotype frequency esti-
mates of > 0.2148 from England, Ireland, Scotland, Wales,
Orkney Islands, Brest, Germany, and Australia, areas pop-
ulated predominantly by persons of Celtic ancestry
[9,11,13,20,22]. These data and the results of studies in
which HLA-DRB1*04 phenotype frequencies were
assessed in melanoma patients are displayed in Table 3.
The frequencies of HLA-DRB1*04 in these countries or
regions are significantly higher than that in Alabama sub-
jects (p ≤ 0.005) (Table 3).
Discussion
The present results indicate that England, Ireland, Scot-
land and the aggregate "British Isles" are the countries of
ancestry reported most frequently by cutaneous
melanoma probands and control subjects in central Ala-
bama. Germany is another country of ancestry often
reported by the present study participants. These results
are consistent with historical accounts of early migrations
of persons of English, Irish and Scots descent into central
Alabama [23-26], with the national associations of sur-
names recorded in Alabama Census returns for 1820 and
1830 [27], and with the present composition of the south-
ern United States [25]. In U.S. Census 2000, country of
ancestry information (maximum of two countries) was
reported on a "long form" provided to one in six census
participants, and was tabulated as numbers of country-
specific reports [28]. Thus, the data of U.S. Census 2000
cannot be compared statistically with the results of the
present study, but the percentages of European countries
of ancestry of white Alabama residents compiled in both
studies reveal similar trends. In the present study, the larg-
est subgroups of reports in the "North, Central, and South
American Countries" category are those of "U.S." or
"American" ancestry. Some participants did not report or
know the country of ancestry of their grandparents. These
findings are also consistent with trends in the U.S. Census
1990 and U.S. Census 2000, in which the percentages of
white Americans who report "American" ancestry are
increasing, and the percentages of those who report vari-
ous European countries of ancestry are decreasing [28,29].
"Native American" ancestry, especially Cherokee or Creek
heritage, was reported by many of the present study par-
ticipants, and this is consistent with accounts of early
Alabama history [24,30-32] and with U.S. Census data on
Alabama since 1820 [27-29]. However, the corresponding
aggregate "Native American" frequency of country ances-
try reports and country of ancestry indices were not signif-
icantly different in melanoma probands and control
subjects. This supports the postulate that native American
ancestry does not contribute significantly to the increased
frequency of cutaneous melanoma in central Alabama.
Table 3: HLA-DRB1*04 Phenotype Frequencies in Central Alabama, European and Australian White Populations.
Country (City or Region) HLA-DRB1*04 Frequency
Melanoma Patients (n) Control Subjects (n)
USA (Central Alabama) 0.3820 (123)‡ 0.2148 (340)‡
England (Manchester) NA 0.3257 (786)†
Wales NA 0.3651 (7,165)†
Ireland (Belfast) NA 0.3422 (5,000)†
Ireland (Dublin) NA 0.3063 (1,910)†
Orkney Island NA 0.3556 (104)†
France (Brest) NA 0.3933 (150)†
Germany (Munich) 0.2350 (98)# 0.2170 (847)#
Australia (Melbourne) 0.5590 (34)¶ 0.3280 (210)¶
NA = Not available ‡Reported in references 9, 20 † Reported in reference 22. # Reported in reference 13 ¶ Reported in reference 11BMC Cancer 2004, 4:47 http://www.biomedcentral.com/1471-2407/4/47
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The percentages of men and women were not significantly
different in cutaneous melanoma probands and control
subjects. Analyses of the two study groups indicate that
age is not significantly correlated with country of ancestry
indices. The mean age of cutaneous melanoma probands
was significantly greater than that of control subjects.
However, the mean number of countries reported by cuta-
neous melanoma probands and control subjects did not
differ significantly. Thus it appears that diagnosis of cuta-
neous melanoma or greater age is not associated with
greater interest or knowledge in personal ancestry,
although this is unproven.
30.0% of cutaneous melanoma probands and 30.1% of
control subjects did not know the country of ancestry of
any of their four grandparents and were thus declared ine-
valuable. Many others did not know the ancestry of some
of their grandparents. Some participants reported that
they were unaware of their ancestry due to adoption, fam-
ily estrangement, or disinterest in genealogy. Other partic-
ipants could have been incorrect in their reporting. The
percentages of evaluable cutaneous melanoma probands
and control subjects who reported grandparents in the
"Don't Know" category were similar. Altogether, it is
unlikely that exclusion of subjects who did not know the
country of ancestry of each of their grandparents would
significantly change the outcomes of the present study.
The overall trends in frequency of country reporting and
country of ancestry indices in "British Isles" and "Europe
Not British Isles" categories in the present study were sim-
ilar. This suggests that uncertainty of participants about
the exact degree of country of ancestry of some of their
grandparents was probably not a significant contributor
to the major conclusions of the present study. It is possi-
ble that control subjects who were included also had cuta-
neous melanoma. Nonetheless, it is unlikely that
identification of a presumably small number of undiscov-
ered control subjects with cutaneous melanoma would
significantly change the conclusions of the present study.
Previous studies reported that Celtic ancestry is a risk fac-
tor for cutaneous melanoma, particularly when people of
Celtic ancestry inhabit areas of high flux of ultraviolet
radiation [4,6]. Persons of Celtic ancestry usually have fair
skin, eyes and hair of light color, poor ability to tan, and
tendency to burn easily after sun exposure [4,6]. Areas of
the British Isles where persons have a high degree of Celtic
ancestry include Wales, Cornwall, Scotland and Ireland
[6]. We did not specifically ask about nor did we receive
reports of Cornwall as a region of origin in the present
study. Similarly, Wales was reported as a country of origin
by none of the present probands and few of the control
subjects. However, the frequency of country reports and
ancestry indices for Ireland, Scotland, aggregate "British
Isles," and combined Ireland and Scotland ("Celts") in
the present melanoma probands was significantly greater
than that in control subjects, consistent with the hypoth-
esis that Celtic ancestry is a risk factor for cutaneous
melanoma.
The present observations are consistent with those of
another study in Alabama in which white persons with
hemochromatosis, a disease thought to be of Celtic origin
[33,34], reported a significantly greater Scotland and
"British Isles" ancestry than controls [17]. The countries of
ancestry reported was also consistent with the relative
high frequency of C282Y, the major allele associated with
hemochromatosis, in Alabama hemochromatosis
probands compared to controls [17].
Using an index of Celtic ancestry that included grandpar-
ental surnames, maiden names, and country of birth to
evaluate persons in Wales, other investigators observed
that "high-scoring Celts" were significantly more likely to
have Fitzpatrick skin type I or II (poor ability to tan, and
tendency to burn easily after sun exposure) [35] than non-
Celtic subjects [14,19]. Moreover, the frequency of HLA-
DRB1*04 was significantly greater in "high-scoring Celts."
These authors concluded that the increased risk of cutane-
ous melanoma and other types of skin cancer in persons
of Celtic ancestry in Wales is due not only to paler skin,
but also to HLA-DRB1*04 and associated immunologic
factors.
Observations from previous studies demonstrate that the
frequency of positivity for the HLA-DRB1*04 phenotype
is significantly greater in Alabama cutaneous melanoma
probands than in control subjects [8,9,20]. This is consist-
ent with reports from Australia and Wales [11,12,14]. Fur-
ther, previous reports from Alabama suggest that the
subgroup of individuals who possess HLA-DRB1*04 are
at increased risk for cutaneous melanoma, independent of
eye color, hair color, amount of melanin in the skin, or
ethnic origin [8]. However, the failure to reach statistical
significance in the comparison of HLA-DRB1*04 pheno-
types in the present 19 "Celts" and the 44 "non-Celts" is
likely due to the small number of probands who reported
Celtic ancestry and for whom HLA typing data were
available.
Investigators in Texas and England reported that the HLA
genotype DQB1*0301 influences either susceptibility to
and/or severity of melanoma [15,36-38]. This conclusion
is consistent with previous studies in which HLA-
DRB1*04 was associated with melanoma, because HLA-
DQB1*0301 is in linkage disequilibrium with HLA-
DRB1*04 [37].
The highest frequencies of HLA-DRB1*04 in Europe occur
in England, Wales, Ireland, the Orkney Islands, and theBMC Cancer 2004, 4:47 http://www.biomedcentral.com/1471-2407/4/47
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Brest area of France [22]. These geographic results could
explain the significantly increased frequency of HLA-
DRB1*04 in cutaneous melanoma probands from central
Alabama, because the present melanoma probands had
significantly higher Ireland, Scotland, and "British Isles"
country of ancestry indices than Alabama control subjects.
Our observations and those of others suggest that certain
HLA genotypes may be markers for Celtic ancestry [8,14].
It has been reported that HLA phenotypes other than
HLA-DRB1*04 occur in association with melanoma in
various white national or ethnic groups [13,15,36,39,40].
This could be explained in part by the variation of HLA
phenotype frequencies in these white national or ethnic
groups or by other genes within the major histocompati-
bility complex in linkage disequilibrium that also play a
major role in mediation of immune responses. Thus, var-
ious HLA phenotypes could be markers for white national
or ethnic groups that also possess certain physical charac-
teristics and immune response genes that increase their
risk for developing cutaneous melanoma.
Conclusions
The present results support our hypothesis, and are also
consistent with the association of cutaneous melanoma
with Ireland, Scotland and "British Isles" ancestry, HLA-
DR phenotypes, and estimations of a northern European
somatic phenotype (eye color, hair color, amount of mel-
anin in the skin) previously reported in white persons
who reside in central Alabama [3,4,8,9]. The present
observations also suggest that targeting white persons
with relatively high "Celtic" or "British Isles" country of
ancestry indices and HLA-DRB1*04 for cutaneous
melanoma prevention and early diagnosis efforts would
be an effective strategy to decrease the morbidity and mor-
tality of this type of malignancy.
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